Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00206518 · ClinicalTrials.gov registry record · Phase 2
Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients
A Phase 2 study, sponsored by Mothaffar Rimawi.
- Completed
- Registry status
- Phase 2
- Development phase
- 167
- Enrollment target
NCT00206518: Completed Phase 2 study, sponsored by Mothaffar Rimawi.
NCT00206518 is a Phase 2 study that has completed, run by Mothaffar Rimawi. The registered enrollment target is 167 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (26% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00206518, a Phase 2 study, has completed, sponsored by Mothaffar Rimawi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 167 participants
- Enrollment target
Study Summary
The purpose of this study is to learn if the biomarker information obtained (learned or received) from the earlier studies can tell us whether or not Taxotere and/or Adriamycin/Cytoxan can cause tumors to become smaller.
Primary Outcome
The patients' pathological response were assessed using Chevalier's system which graded the responses into Chevalier 1, 2, 3A, 3B, 3C, 3D, and 4, defined as: 1. Disappearance of all tumor either on macroscopic or microscopic assessment in both the breast and LN (pCR) 2. Presence of in situ carcinoma in the breast. No invasive tumor in breast and no tumor in LN (pCR) 3. Presence of invasive cancer with stromal alteration such as sclerosis or fibrosis (pPR) 3A: Subjectively \> 75% therapeutic eff
Interventions
- DRUG doxorubicin
- DRUG Taxotere/Docetaxel
- DRUG Adriamycin/Cytoxan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 167 participants |
| Start Date | 2004-09 |
| Est. Completion | 2016-10-10 |
| Phase | Phase 2 |
What the finished NCT00206518 record still lists
NCT00206518 is an interventional study that assigns participants to a tested intervention. The registered 167 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (26% higher).
The record links to 0 conditions, and to 3 interventions - of which doxorubicin is the first listed.
NCT00206518 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00206518 about?
NCT00206518 is a clinical study titled "Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients". The purpose of this study is to learn if the biomarker information obtained (learned or received) from the earlier studies can tell us whether or not Taxotere and/or Adriamycin/Cytoxan can cause tumors to become smaller.
What is the current status of trial NCT00206518?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 167 participants. The study started on 2004-09. Estimated completion is 2016-10-10.
What interventions are being tested in trial NCT00206518?
The interventions under investigation include: doxorubicin (DRUG), Taxotere/Docetaxel (DRUG), Adriamycin/Cytoxan (DRUG).
Who is sponsoring clinical trial NCT00206518?
This trial is sponsored by Mothaffar Rimawi, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00206518's enrollment target sits among peer trials
167 406th of 2000 higher than 1,595 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04248283 · 167 participants · NA
Adjustable Continence Therapy (ACT) for the Treatment of Female SUI
- NCT04552509 · 167 participants · NA
TRUEBEAM Stereotactic Body Radiotherapy for Localized Prostate Cancer
- NCT05516277 · 167 participants · NA
Insomnia Treatment and Cardiometabolic Health in Older Adults With Posttraumatic Stress Disorder
- NCT02118922 · 168 participants
A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia